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Abstract {#sec1-1}
========

The outcome of patients underwent to allogeneic stem cell transplantation (allo- SCT) is closely related to graft *versus* host disease (GvHD) and graft *versus* leukemia (GvL) effects which can be mediated by mHAgs. 23 mHAgs have been identified and reported to be differently correlated with GVHD or GVL and the aim of this work was develop a method to genotype the mHAgs described so far. For this study we used MALDI-TOF iPLEX Gold Mass Array technology. We tested 46 donor/recipient matched pairs that underwent allo-SCT because of Philadelphia positive (Ph+) chronic myeloid leukemia (n=29) or Ph+ acute lymphoblastic leukemia (n=17). Our data show that sibling pairs had a lesser number of mHAgs mismatches compared to MUD pairs. Notably, donor/recipient genomic mismatch on DPH1 was correlated with an increased risk of acute GvHD and LB-ADIR-1R mismatch on graft *versus* host direction was correlated with a better RFS with no increase of GvHD risk. Our work provides a simple, accurate and highly automatable method for mHAgs genotyping and suggest the role of mHAgs in addressing the immune reaction between donor and host.

Introduction {#sec1-2}
============

Allogeneic stem cell transplantation (allo-SCT) may be the only cure for patients affected by acute myeloid or lymphoid leukemia, or other hematological diseases such as lymphomas or multiple myeloma.^[@ref1]^

The curative effects of allo-SCT are closely related to graft *versus* leukemia (GvL). However the severity of the graft *versus* host disease (GvHD) may override the GvL benefit and worsen the outcome of allotransplanted patients.^[@ref1]^ Despite a full major HLA antigens (MHAgs) compatibility, minor histocompatibility antigens (mHAgs) can also play a pivotal role in conditioning both GvL and GvHD response in HLA full-matched allo-SCT. Evidence from experimental and clinical studies on HLA-identical allo-SCT suggest that GvL and GvHD may be driven by donor T cell responses against disparate mHAgs.^[@ref4]^ Indeed, mHAgs are polymorphic HLA-bound peptides derived from cellular proteins that can induce powerful alloreactive T cell responses. The mHAgs recipient-donor disparity may arise from a genomic variation in the coding region of the gene that leads to differences in the amino acid sequence of the homologous protein and, in most cases, it may depend on a nonsynonymous single nucleotide polymorphism (nsSNP) or on a deletion.^[@ref7],[@ref10],[@ref11]^ Recent advances in the molecular identification of mHAgs have significantly expanded our knowledge to a total of 23 autosome-coded mHAgs and 10 Y-chromosome coded mHAgs, leading to an increased interest in the clinical application of mHAgs typing. Although several mHAgs, including Y-chromosome encoded mHAgs, are ubiquitously expressed, an increasing number of autosomal-encoded mHAgs is being identified as expressed exclusively by hematopoietic cells or by their malignant counterparts.^[@ref12]^

About this, ACC-1, ACC-2 and HA-2 have been correlated with the beneficial GvL effects, while some mHAgs disparities, CD31, HA-5, HA-8 and UGT2B17, have been found to be involved in the induction of GvHD.^[@ref8],[@ref22]^

The molecular identification of GvHDand GvL-associated mHAgs could allow the evaluation of the clinical impact of mHAgs mismatches and their specific T cell responses triggered by allo-SCT. Several studies in HLA-matched allo-SCT reported an association between mHAgs mismatches and the clinical outcome,^[@ref29]^ but other studies have not confirmed these observations.^[@ref7],[@ref24]^

The heterogeneity of techniques suitable for mHAgs typing (SSP-PCR and Luminex) as well as the complexity of integrating mHAgs typing data and clinical information are likely the main reasons that do not facilitate the routinary evaluation of mHAgs in clinics.^[@ref34]^ In our study, we set up a new method for mHAgs genotyping based on Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) mass spectrometry (MS) and we tested it in a training set of donor-recipient pairs with the aim to propose a simple and standardizable methodology able to overcome the limits of the conventional methods and to make mHAgs genotyping suitable for clinical application.^[@ref37]^

Materials and Methods {#sec1-3}
=====================

Patients and transplant procedures {#sec2-1}
----------------------------------

For this study, we tested the MALDITOF iPLEX Gold method on a cohort of Ph+ CML and Ph+ ALL patients who underwent allo-SCT at six Italian Centres from 1990 to 2011. To this purpose, we retrospectively selected 46 donor-recipient pairs fully HLA compatible for HLA-A, -B, -C, -DRB1 and -DQB1 alleles, according to SSP-PCR high resolution molecular methods. Out of the 46 selected cases, 29 were Ph+ CML and 17 were Ph+ ALL patients who underwent allo- SCT by sibling (29 cases, 63%) or MUD (17 cases, 37%).

GvHD effects, either acute or chronic, were defined according to the Glucksberg scale and NHI criteria, respectively, and they were reported as cumulative incidence. Relapse free survival (RFS) was calculated using Kaplan-Meier method and it was assumed as an indicator of GVL effect.^[@ref39]^ All patients provided informed consent according to the policy of each participating Centre. Patients and transplant features are reported in [Table 1](#table001){ref-type="table"}.

mHAgs's biological characteristics and definitions {#sec2-2}
--------------------------------------------------

The HLA matched donor-recipient pairs evaluated for this study were genotyped for a panel of 23 mHAgs (and causal SNPs). The biological characteristics of each mHAg (gene, *locus*, SNP reference number, nucleotide switch and HLA restriction) are detailed in [Table 2](#table002){ref-type="table"}. We specify that CD31 exists in two isoforms (CD31125 and CD31563) because it results from two different SNPs (rs668 and rs12953, respectively). We genotyped both SNPs, but we considered the two isoforms together during the analysis because of the strong linkage between the two SNPs. On the contrary, the SNP rs2289702 determine two different mHAgs, ACC-4 and ACC-5, according to the HLA molecule that present them.

For the purpose of this study, immunogenic mHAg difference was defined when within a given donor/recipient pair, only one individual had an immunogenic phenotype of a particular mHAg accompanied by the appropriate HLA restriction molecule. Genomic mHAg difference was identified when mHAg genotypes in donor and recipient were different, but phenotypically they were either the same or the mHAg immunogenic phenotype was not accompanied by the appropriate HLA restriction molecule. Both genomic and immunogenic mHAgs disparities were included in the analysis. This is due to an incomplete knowledge of mHAgs because the epitope-prediction strategy often makes it hard to confirm the immunogenicity of the predicted putative mHAgs and there is currently no controlled way of isolating mHAgs-specific T cells directed against mHAgs.

mHAgs genotyping by MALDI-TOF iPLEX Gold technology {#sec2-3}
---------------------------------------------------

For the purpose of our study, the genomic DNA (gDNA) was extracted using QIAamp DNA mini Kit (Qiagen) from peripheral blood mononuclear cells (PBMC) previously cryopreserved. The PBMC collection was performed before allo-SCT for patients and before stem cells harvest for donors. The purity of gDNA for each sample was determined by measuring the absorbance at 260 and 280 nm, with the A260/A280 values being in the range of 1.5-1.9, and the concentration of the gDNA was adjusted to 12 ng/μL. A total of 30 ng of gDNA was used for genotyping all SNPs.

MS MALDI-TOF iPlex Gold is able to discriminate the two variants of an SNP in a very efficient way, so it was considered suitable for the aim of the study. The MassARRAY Assay Design software was used to design 3 different multiplex reactions to investigate the 23 SNPs. Genotyping was performed using iPLEX Gold technology and MassARRAY high-throughput DNA analysis with matrix-assisted laser desorption/ionization time-of-flight (MALDI□TOF) MS \[Agena Bioscience Inc., San Diego, CA\], according to the manufacturer's protocol.^[@ref41]^ Multiplex design and primer sequences are shown in [Table 3](#table003){ref-type="table"}.

The multiple-genotyping assay was validated using intra- and extra-run controls. Firstly, a DNA sample (NA10859) from the CEPH (Centre d'Etude du Polymorphisme Humain CEPH, Paris, France) panel was genotyped simultaneously in every single run. Six mHAgs (ACC-1, ACC-2, ACC-6, HA-8, HB-1 and LB-ADIR-1R) were reported. Then, the genotype of each polymorphism was validated in 10 randomly selected samples by amplification with PCR and subsequent direct Sanger Sequencing (ABI Prism 3730, Applied Biosystems, Foster City, CA) as gold standard.

Statistical analysis {#sec2-4}
--------------------

For continuous factors, the median and ranges were calculated. The χ^[@ref2]^-test was used to compare differences in percentage, and Mann-Whitney U test was used to compare continuous values. The probability of GvHD (acute and chronic) was estimated as cumulative incidence. In GvHD analysis, competing risks were relapse or death before the onset of GvHD. Probabilities for RFS were calculated using the Kaplan-Meier method.^[@ref42]^ RFS was calculated from the date of allo-SCT until the date of relapse or death, whichever occurred first. Death in remission was considered as a competing risk in the relapse analysis. Differences in RFS were evaluated by log-rank testing in univariate analysis. Multivariate analyses were performed using the Fine and Gray regression model. The Cox proportional hazard regression model was used for multivariate analyses of variables affecting RFS. The following patient- and transplantrelated variables were analyzed: CML or ALL diagnosis and type of bcr-abl transcript, immunogenic/genomic mHAgs mismatches between donor and recipient, patient age at SCT, type of donor, patient gender and sex mismatch between donor and recipient, graft source, time from diagnosis to HSCT, conditioning regimen, GvHD prophylaxis and development of GvHD. All P-values were 2-sided and P\#x003C;0.05 was considered statistically significant. Each SNP was tested for departures from the Hardy-Weinberg equilibrium (HWE).

Results {#sec1-4}
=======

SNPs genotyping by MALDI-TOF iPLEX Gold technology {#sec2-5}
--------------------------------------------------

The MALDI-TOF iPLEX Gold technology method was used on a training group of 46 donor/recipient pairs with the aim to evaluate the accuracy and reliability of the genotyping assay. A total of 2116 genotypes resulted out of a predicted total number of 2116 (92 samples for 23 SNPs) with a call rate of 100%.

In order to evaluate the accuracy and reliability of the genotyping assay, two different approaches were adopted. Evaluation of method reproducibility was carried out by genotyping of the DNA number NA10859 during the Sequenom run. This standard DNA is released the genotype of only six (6 of 23, 26%; ACC-1, ACC-2, ACC-6, HA-8, HB-1 and LB-ADIR-1R) mHAgs. The concordance between the released data and our genotyping was 100%. In the second stage, we validated the set of 10 randomly selected samples using conventional Sanger sequencing and also in this case we obtained a concordance of 100%. The Hardy-Weinberg equilibrium (HWE) was satisfied for most SNPs on both populations (patients and donors). rs12692566 (mHAgs LB-LY751K) was the only SNP showing a significant difference as compared with the prediction under HWE assumptions. Since Hardy Weinberg disequilibrium can indicate genotyping errors or population stratification, LBLY751K was excluded from the statistical analysis ([Table 4](#table004){ref-type="table"}).

mHAgs mismatches, patients' clinical features and correlation with GvHD/GvL effects {#sec2-6}
-----------------------------------------------------------------------------------

The analysis of immunogenic mismatches showed that sibling pairs had a lesser number of mismatches compared to MUD pairs (median 1 *vs*. 3; t-test with P\<0.003). The evaluation of genomic mismatches point out that sibling pairs have higher identity than MUD pairs (t-test, P\<0.0001). In fact, the median number of genomic differences was 8 (range 0-15) in sibling pairs and 13 (range 11-17) in MUD pairs (t-test with P\<0.05). Only one sibling pair showed a perfect genomic mHAgs match.

We also tried to correlate if some mHAgs mismatches could be involved in GvHD development. DPH1 genomic mismatch resulted to be correlated with the risk of grade ≤2 aGvHD development (multivariate analysis HR 2.2, P=0.04, [Table 5](#table005){ref-type="table"}), while no mHAgs mismatches were found to be correlated with an increased risk of cGvHD ([Table 5](#table005){ref-type="table"}).

By these evidences, we investigated any correlation between mHAgs mismatches and RFS as a clinical surrogate of GvL effect. Despite some clinical factors affecting the RFS (*i.e.* the underlying disease, b3a2 transcript isoform and chronic GvHD development), in multivariate analysis we observed that only LB-ADIR-1R, with genomic mismatch on graft versus host direction (HR 0.3, P=0.03, [Table 5](#table005){ref-type="table"}) was positively correlated with a better RFS.

Discussion {#sec1-5}
==========

The study aimed to set up a new laboratory assay for genotyping minor histocompatibility antigens which are thought to play a key role in the allo-immune responses in fully HLA-matched stem cell transplantations.

The MALDI-TOF iPLEX gold approach was used to overcome the limits of conventional methods, such as SSP-PCR and Luminex, and to make mHAgs genotyping analysis suitable for clinical application. PCR-SSP and Luminex are commonly used for HLA typing, but both methods have several limitations. Complex primer design and identification of the annealing temperature are critical for the PCR-SSP test; while biotinylated DNA probes, beads and streptavidin-phycoerythrin binding are critical steps for Luminex.^[@ref34],[@ref35]^MALDI-TOF was used effectively for KIR (killer-cell immunoglobulin-like receptor) and platelet antigens genotyping and, due to the expected advantages in terms of rapidity, simplicity and high throughput capability, it was identified as a potential new method for mHAgs genotyping.^[@ref36],[@ref37]^ From a technical point of view, one of the main advantages of SNPs genotyping by MS system consists in the direct measurement of the mass of the molecules of interest without using any surrogate, such as fluorescence. MS genotyping has shown high accuracy; moreover, this methodology is rapid and highly automated, with a genotyping throughput of up to 128 matched pairs (256 samples) per run. The MS approach presents other advantages: it requires only a small amount of DNA, it is highly reproducible, and, furthermore, it works on multiplex and the design of each multiplex is made directly by the instrument software. The only drawbacks of this method are that it does not allow the genotyping of mHAgs resulting from deletions and can be used only if both the polymorphism and the polymorphism's flanking region are known.^[@ref36]^ The use of designed primers for SNPs of interest and the MS protocol in this training set allowed us to genotype 100% of the SNPs (2116 genotypes of a predicted total number of 2116) and mHAgs. Intra- and extra-run controls demonstrated the reliability of this method. Analyzing the data obtained by genotyping the mHAgs of this set of donor/recipient pairs with their clinical features, particularly GvHD development and RFS, some interesting suggestions have emerged.

Sibling pairs have fewer mHAgs disparities despite the pairs with HLAmatched unrelated donor (P\<0.0001). This data may appear obvious, but from a biological point of view no study has clearly shown that until now. This means that the genomic compatibility of HLA full matched MUD pairs will never be greater than full HLA sibling pairs.

Established that HLA differences between donor and recipient are the major predictor of GvHD, we investigated a possible role of mHAgs on GvHD development and relapse incidence in a training set of Ph-positive CML and ALL allotransplanted patients. These patients were chosen because representative of chronic and acute leukemias sharing a unique cytogenetic alteration: t(9;22). The only observation is that genomic DPH1 mismatch appeared to be related to an increased risk of grade ≤2 aGvHD development. This possible correlation between DPH1 and aGvHD is supported by the fact that DPH1 is expressed by a broad range of non-hematopoietic tissues. The role of DPH1 on extramedullary toxicity has already been described by Warren, who pointed out that pulmonary toxicity was observed with infusion of DPH1-specific T cells. On the contrary, leukemic blasts were poorly recognized by DPH1-specific T cells.^[@ref43]^

Conversely, we found that genomic mismatch of LB-ADIR-1R on graft versus host direction was related to a better RFS. Our findings on LB-ADIR-1R mismatch are consistent with previous data from van Bergen, showing that LB-ADIR-1R specific T cells perform wide-reaching antitumor activity with a limited recognition of nonactivated tissues. Indeed, LB-ADIR-1R specific T cell recognize cell lines from haematological tumours, while generally mesenchymal and biliary epithelial cells are recognized to be GvHD target tissues.^[@ref14]^

Conclusions {#sec1-6}
===========

This work prove that MS may be a simple, effective, and accurate method for mHAgs genotyping. The method requires a small amount of gDNA that can be easily extracted also from cryopreserved cells. Furthermore, MS is able to genotype all mHAgs in a single work session, thus saving a lot of time.

Data analysis of our patients training set lead us to say that despite the full major HLA match, the minor-HLA genomic and immunogenic compatibility between a patient and his unrelated donor is always lower compared to the genomic and immunogenic compatibility of a patient and his sibling donor. In fact, sibling pairs had a lesser number of mHAgs mismatches compared to MUD pairs (P=0.003). Of 23 mHAgs evaluated, only 2, DPH1 and LBADIR- 1R, proved to be correlated with the GvHD and GvL effect respectively, and these results confirm the previous reports. Our study suggests that MS would be used and useful for mHAgs genotyping. A larger and prospective trial would be warranted to validate this method.

###### 

Patients and HSCT characteristics.

  Characteristic                          N.     \%
  --------------------------------------- ------ ---------
  Age, mean (range)                       36.5   17-67
  Male                                    27     59
  Male-female sex mismatch                9      19
  Matched sibling donor                   29     63
  Matched unrelated donor                 17     37
  Ph + CML                                29     63
           CP                             23     79
           AP/BP                          6      21
  Ph + ALL                                17     37
           1^st^ CR                       12     71
           2nd CR                         2      12
           Relapse                        3      18
  Stem cell source                                
           Mobilized peripheral blood     24     52
           CD34 ×106/kg, median (range)   5.07   2.2-8
           CD3 ×106/kg, median (range)    162    4.7-350
           Bone marrow, n (%)             19     17-Feb
           CD34 ×106/kg, median (range)   3.2    2.8-4
           CD3 ×106/kg, median (range)    23.5   20-40
  Interval between diagnosis and SCT              
           ≤1 year                        24     52
           \>1 year                       17     37
           Not available                  5      11
  Date of SCT                                     
           1990-1999                      19     41
           2000-2012                      27     59
  Conditioning regimens                           
           Busulfan based                 27     59
           TBI based                      17     37
           Others                         2      4
  GvHD prophylaxis                                
           Cyclosporine/MTX               46     100
  Gratwohl score                                  
           1                              6      13
           2                              12     26
           3                              11     24
           4                              6      13
           5                              4      9
           ≤6                             1      2
           ND                             6      13

CP, chronic phase; AP/BP, accelerate phase/blastic phase; CR, complete remission; TBI, total body irradiation; MTX, methotrexate.

###### 

mHAgs biological features.

  mHAg           Gene          Gene locus   Tissue expressione   SNP reference   Nucleotide switch   HLA           Ref.   
  -------------- ------------- ------------ -------------------- --------------- ------------------- ------------- ------ ------------------------------
  ACC-1          Bcl2A1        15q24.3      Hemopoietic          rs1138357       G→A                 A\*24         25     \[3, 28, 32, 26, 16\]
  ACC-2          Bcl2          15q24.3      Hemopoietic          rs3826007       G→A                 B\*44         17     \[3, 28, 32, 26\]
  ACC-4          Catepsina H   15q24-25     Hemopoietic          rs2289702       G→A                 A\*33:03      0      \[6, 28\]
  ACC-5          Catepsina H   15q24-25     Hemopoietic          rs2289702       G→A                 A\*31:01      0      \[6, 28\]
  ACC-6          HMSD          18q21.33     Hemopoietic          rs9945924       G→A                 B\*44         17     \[6\]
  C19orf48       C19orf48      19q13        Broad                rs3745526       A→T                 A\*02:01      46,5   \[6, 19\]
  CD31           PECAM1        17q23        Broad                rs668           C→G                 A\*02         52     \[27\]
  CD31           PECAM1        17q23        Broad                rs12953         A→G/T               A\*02         52     \[7, 29\]
  CTL7A7         PANE-1        22q13.2      Hemopoietic          rs5758511       C→T                 A\*03         20     \[18, 28, 32\]
  DPH1           DPH1          17           Broad                rs35394823      C→G                 B\*5701       4      \[28\]
  DRN-7          SP110         2q37.1       Hemopoietic          rs1365776       G→A                 A\*03         20     \[28, 32\]
  HA-1           KIA A0223     19p13.3      Hemopoietic          rs1801284       A→G                 A\*02,        52,    \[32\]
                                                                                                     A\*02:06;     0,      
                                                                                                     B\*40:01      0       
  HA-2           MYOG 1        7p13-p11.2   Hemopoietic          rs61739531      G→A                 A\*02:01      46,5   \[3, 7, 22, 28, 32, 26\]
  HA-3           LBC           15q24-25     Broad                rs7162168       T→C                 A\*01         21     \[3, 10, 27, 28, 32\]
  HA-8           KIA A 0020    9p24.2       Broad                rs2173904       G→C                 A\*02:01      46,5   \[3, 7, 10, 15, 28, 32, 25\]
  HB-1           HB-1          5q31.3       Hemopoietic          rs161557        C→T                 B\*44:02,     7,     \[3, 13, 28, 32, 26\]
                                                                                                     B\*44:03      20      
  HEATR-1        HEATR-1       1q43         Broad                rs2275687       C→T                 B\*08:01      10     \[26\]
  LB-ADIR-1R     TOR3A         1q25.2       Hemopoietic          rs2296377       T→C                 A\*02:01      46,5   \[28\]
  LB-ECGF-1H     ECGF          22q13.33     Hemopoietic          rs112723255     C→T                 B\*07         11     \[28\]
  LB-LY75-1K     Ly75          2q24.2       Hemopoietic          rs12692566      T→G                 DRB1\*13:01   11     \[20\]
  LB-MTHFD1-1Q   MTHFD1        14           Hemopoietic          rs2236225       G→A                 DRB1\*03:01   14     \[20\]
  LB-PTK2B-1T    PTK2B         8            Hemopoietic          rs751019        A→C                 DRB3\*01:01   nd     \[20\]
  P2RX7          P2RX7         12           Broad                rs7958311       A→C/G/T             DRB1\*03      16     \[26\]
  UTA2-1         C12orf75      12           Broad                rs2166807       A→G                 A\*02         52     \[3\]

###### 

Primers using for MALDI-TOF assays are listed; PCR primers tags are in bold, no-template bases are reported in lower case letters.

  Multiplex   mHAg         SNP           Amplification Primer             Extension Primer                  
  ----------- ------------ ------------- -------------------------------- --------------------------------- ------------------------------
  1           ACC-1        rs1138357     ACGTTGGATGTTGGACCTGATCCAGGTTGT   ACGTTGGATGTATTTACAGGCTGGCTCAGG    GTGGTATCTGTAGGACG
              ACC-2        rs3826007     ACGTTGGATGTGGTTACAATTCTTCCCCAG   ACGTTGGATGCTGCCAGAACACTATTCAAC    tcCAATTCTTCCCCAGTTAATGATG
              ACC-6        rs9945924     ACGTTGGATGGAAGTCCAGCTCAACTGATA   ACGTTGGATGCACTGCAGCTCAGATGTCTC    TTGTCTTGAAGTGGCTTTA
              C19orf48     rs3745526     ACGTTGGATGCACGCCTAGGCAGGAAACA    ACGTTGGATGTTTTCTGTGTCCTTCCCCTG    GCCTAGGCAGGAAACAGCAGAG
              DRN7         rs1365776     ACGTTGGATGCTTCCTCTTGTACTCTCATC   ACGTTGGATGAGATGTATCTGGTCAACTCC    aaTCTTGTACTCTCATCTTACCTC
              HA-1         rs1801284     ACGTTGGATGGCCTTGAGAAACTTAAGGAG   ACGTTGGATGTTGGGTCTGGCTCTGTCTTC    AGGAGTGTGTGTTGC
              HA-2         rs61739531    ACGTTGGATGATGGCCTCAGGCCCATACAG   ACGTTGGATGCGCATCTACACCTACATCGG    aTCCTGGTAGGGGTTCA
              HA-8         rs2173904     ACGTTGGATGGTTTTGTTGCAGTCAGCAG    ACGTTGGATGGTTCTAATTTTTCTGGCTG     TGTTGCAGTCAGCAGATCACC
              LB-ADIR-1R   rs2296377     ACGTTGGATGGTCCGTGGCGCCAGCTTTG    ACGTTGGATGTGGAGGCGCCGCGGGGCTCA    CCAGCTTTGGCTCTTT
              LB-ECGF1     rs112723255   ACGTTGGATGAGGAGGCGCTCGTACTCTC    ACGTTGGATGAAGGAGCTTTATTGCTGCGG    gCGTACTCTCCGACCGC
              LB-LY751K    rs12692566    ACGTTGGATGTGGGGTCTTATCAAACCAC    ACGTTGGATGGTCTTGATTTAATCTCTAAGC   GGTCTTATCAAACCACATAAGAGA
              LB-MTHFD1    rs2236225     ACGTTGGATGTAACCTACAAACCCTTCTGG   ACGTTGGATGACATCGCACATGGCAATTCC    ccCTGGGCCAACAAGCTTGAGTGCGATC
              P2RX7        rs7958311     ACGTTGGATGTGGTGGTCTTGTCGTCAAGG   ACGTTGGATGAGATCTACTGGGACTGCAAC    gCAAGGCGACGGAAACTGTATTTGGGA
              UTA2-1       rs2166807     ACGTTGGATGAGCTGAGGTCTGCCTTGATG   ACGTTGGATGACCACATACATCATTGCAAG    CTTGATGGTAAAGTTAATACAGAATTT
  2           ACC-4/5      rs2289702     ACGTTGGATGACCGCAGACGGGGACTCCCA   ACGTTGGATGATGTGGGCCACGCTGCCGCT    TCCCAGGAGCCAGGCCC
              CD31         rs668         ACGTTGGATGGCTCAGTTCCAAGGACTCAC   ACGTTGGATGGTACTGTGATTGTGAACAAC    CACCTTCCACCAACA
              CTL7A7       rs5758511     ACGTTGGATGTTGAGCACACCAGGCAAGTC   ACGTTGGATGACGGAGATACCTCGTGGAAG    CACACCAGGCAAGTCCCACACTC
              DPH1         rs35394823    ACGTTGGATGTGCTGCTCTCTGAGATCTTC   ACGTTGGATGATAGCCAGGCAGATACTCAC    CCCAGCAAGCTTAGC
              HA-3         rs7162168     ACGTTGGATGATGATGATGGGGCCCCAGC    ACGTTGGATGTAGAGAGGGAGTGCTCCTTT    cCTGGTGTGAGGGAAGTCA
              HB-1         rs161557      ACGTTGGATGCTCAAGTCTCAGCTAAGCCA   ACGTTGGATGCTTCAACTTCAACCAATTCC    CCATTCTTTTCTATAGGTTCTCTG
              HEATR1       rs2275687     ACGTTGGATGCTTCCTTTTTGATACCCAGC   ACGTTGGATGTGGTTACCTGATCCACCAGA    TTTATAAGTAAAGAGAGAGCAG
              LB-PDK2B     rs751019      ACGTTGGATGTGTTTCTTCCTCTGCAGGAC   ACGTTGGATGTCTCCTGGCAACTCACCAAT    CCCCATGGTTTATATGAATGATA
  3           CD31         rs12953       ACGTTGGATGGGCTGTGCAGTAATACTCTC   ACGTTGGATGAATGCCACCCAGGCATTTTG    CCCTCCTGTTCCTTG

###### 

Hardy-Weinberg equilibrium.

                                                   Patients and Donors   Patients   Donors                                                                         
  ------------ ------------- --- --- ------- ----- --------------------- ---------- -------- ------ ----- ------- ------ ------ ------ ----- ------- ------ ------ ------
  ACC-1        Rs1138357     G   A   0,612   1,2   0,17                  62,3       30,9     6,8    1,2   0,514   61,7   32,1   6,2    1,2   0,195   63     29,6   7,4
  ACC-2        rs3826007     G   A   0,438   1,2   0,26                  63         30,9     6,1    1,2   0,77    63     32,1   5      1,2   0,198   63     29,6   7,4
  ACC-4Æ       rs2289702     C   T   0,568   0     0,249                 78,7       21,3     0      0     0,265   78     22     0      0     0,296   79,3   20,7   0
  ACC-6        rs9945924     G   A   0,79    1,2   0,323                 54,3       40,7     5      1,2   0,633   55,6   38,3   6,1    1,2   0,198   53,1   43,2   3,7
  C19orf48     rs3745526     A   T   0,796   1,2   0,26                  63         30,9     6,1    1,2   0,199   66,7   27,1   6,2    1,2   0,737   59,3   34,6   6,1
  CD31         rs668         C   G   0,43    0     0,622                 26,2       51,8     22     0     0,757   29,3   51,2   19,5   0     0,658   23,2   52,4   24,4
               Rs12953       G   A   0,391   1,2   0,311                 31,5       45,7     22,8   1,2   0,743   27,2   48,1   24,7   1,2   0,295   35,8   43,2   21
  CTL7A7       rs5758511     G   A   0,474   0     0,572                 51,8       39       9,2    0     0,843   48,8   41,5   9,7    0     0,537   54,8   36,6   8,6
  DPH1         rs35394823    G   C   0,185   0     0,303                 85,4       14,6     0      0     0,6     89     11     0      0     0,365   81,7   18,3   0
  DRN7         Rs1365776     A   G   1       1,2   0,046                 40,1       51,8     8,1    1,2   0,503   42     48,1   9,9    1,2   0,03    38,3   55,6   6,1
  HA-1         Rs1801284     G   A   0,639   1,2   0,453                 35,2       50,6     14,2   1,2   0,512   33,3   51,8   14,9   1,2   0,353   37     49,4   13,6
  HA-2         rs61739531    C   T   0,167   1,2   0,587                 66         29,6     4,4    1,2   0,318   64,2   28,3   7,5    1,2   0,318   67,9   30,9   1,2
  HA-3         rs7162168     C   T   0,424   0     0,285                 50         38,4     11,6   0     0,222   53,7   35,4   10,9   0     0,579   46,3   41,5   12,2
  HA-8         rs2173904     G   C   0,423   1,2   0,659                 43,2       43,8     13     1,2   0,503   46,9   40,7   12,4   1,2   0,956   39,5   46,9   13,6
  HB-1/HY      rs161557      C   T   0,45    0     0,885                 70,1       27,4     2,4    0     0,73    68,3   28     3,7    0     0,511   72     26,8   1,2
  HEATR-1      rs2275687     C   T   0,206   0     0,92                  39,6       47       13,4   0     0,963   42,7   45,1   12,2   0     0,82    36,6   48,8   14,6
  LB-ADIR-1R   rs2296377     G   A   0,043   1,2   0,705                 52,5       40,7     6,8    1,2   0,996   60,5   34,5   5      1,2   0,493   44,4   46,9   8,7
  LB-ECGF-1H   rs112723255   C   T   0,346   1,2   0,43                  89,5       9,9      0,6    1,2   0,37    86,4   12,4   1,2    1,2   0,73    92,6   7,4    0
  LB-LY751K    rs12692566    A   C   0,004   1,2   0,279                 64,8       29,6     5,6    1,2   0,044   61,7   28,4   9,9    1,2   0,326   67,9   30,9   1,2
  LB-MTHFD1    rs2236225     C   T   0,316   1,2   0,78                  34,6       47,5     17,9   1,2   0,176   34,6   42     23,4   1,2   0,296   34,6   53,1   12,3
  P2RX7        rs7958311     G   A   0,709   1,2   0,313                 58,6       34       7,4    1,2   0,853   58     35,8   6,2    1,2   0,218   59,3   32,1   8,6
  LB-PDK2B     rs751019      C   A   0,356   0     0,312                 26,8       53,7     19,5   0     0,449   28     53,7   18,3   0     0,494   25,6   53,7   20,7
  UTA2-1       rs2166807     G   A   0,53    1,2   0,118                 66,7       32,1     1,2    1,2   0,318   67,9   30,9   1,2    1,2   0,228   65,4   33,3   1,2

AA, homozygous dominant allele; aa, homozygous recessive allele; Aa, heterozygous genotype.

###### 

Multivariate analysis of relationship btween mHAgs and aGvHD, cGvHD or RFS.

               Grade a2 aGvHD, HR (p)        cGvHD, HR (p)   RFS, HR (p)
  ------------ ----------------------------- --------------- -----------------------------
  ACC-I        ns                            ns              ns
  ACC-2        ns                            ns              
  ACC-4        ns                            ns              ns
  ACC-5        ns                            ns              ns
  ACC-6        ns                            ns              ns
  CI9orf48     ns                            ns              ns
  CD31         ns                            ns              ns
  CTL7A7       ns                            ns              ns
  DRN7         ns                            ns              ns
  DPHI         2.2 (0.04) genomic mismatch   ns              ns
  HA-1         ns                            ns              ns
  HA-2         ns                            ns              ns
  HA-3         ns                            ns              ns
  HA-8         ns                            ns              ns
  HB-1         ns                            ns              ns
  HEATRI       ns                            ns              ns
  LB-ADIR-IR   ns                            ns              0.3 (0.03) genomic mismatch
  LB-ECGFI     ns                            ns              ns
  LB-MTHFDI    ns                            ns              ns
  LB-PDK2B     ns                            ns              ns
  P2RX7        ns                            ns              ns
  UTA2-I       ns                            ns              ns

aGvHD: acute graft versus host disease; cGvHD: chronic graft versus host disease; GvL: graft versus leukemia; RFS: relapse free survival, RFS has been considered as surrogate marker of GvL
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